Literature DB >> 30953211

Comparison of in vitro activity of the nitroimidazoles delamanid and pretomanid against multidrug-resistant and extensively drug-resistant tuberculosis.

Shu'an Wen1, Wei Jing2, Tingting Zhang1, Zhaojing Zong1, Yi Xue1, Yuanyuan Shang1, Fen Wang1, Hairong Huang3, Naihui Chu4, Yu Pang5.   

Abstract

Delamanid exhibited greater in vitro potency than pretomanid against multidrug-resistant (MDR-) and extensively drug-resistant tuberculosis (XDR-TB) isolates. The pretomanid minimum inhibitory concentration (MIC) values of four MDR-TB isolates were found to be resistant to delamanid ranging from 0.031 to 0.063 mg/L. A novel nonsynonymous mutation within the fbiA gene (Glu249Lys) may be contributing to high-level resistance to delamanid and pretomanid in Mycobacterium tuberculosis.

Entities:  

Keywords:  Delamanid; Minimum inhibitory concentration; Mycobacterium tuberculosis; Pretomanid; Susceptibility

Mesh：

Substances：

Year:  2019        PMID： 30953211     DOI： 10.1007/s10096-019-03551-w

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN： 0934-9723            Impact factor:   3.267


  10 in total

1.  Characterization of Genomic Variants Associated with Resistance to Bedaquiline and Delamanid in Naive Mycobacterium tuberculosis Clinical Strains.

Authors:  S Battaglia; A Spitaleri; A M Cabibbe; C J Meehan; C Utpatel; N Ismail; S Tahseen; A Skrahina; N Alikhanova; S M Mostofa Kamal; A Barbova; S Niemann; R Groenheit; A S Dean; M Zignol; L Rigouts; D M Cirillo
Journal:  J Clin Microbiol       Date:  2020-10-21       Impact factor: 5.948

Review 2.  Pretomanid: First Approval.

Authors:  Susan J Keam
Journal:  Drugs       Date:  2019-11       Impact factor: 9.546

3.  Cofactor F420: an expanded view of its distribution, biosynthesis and roles in bacteria and archaea.

Authors:  Rhys Grinter; Chris Greening
Journal:  FEMS Microbiol Rev       Date:  2021-09-08       Impact factor: 16.408

4.  Superior Efficacy of a Bedaquiline, Delamanid, and Linezolid Combination Regimen in a Mouse Tuberculosis Model.

Authors:  Elise D Pieterman; Lina Keutzer; Aart van der Meijden; Sanne van den Berg; Han Wang; Matthew D Zimmerman; Ulrika S H Simonsson; Hannelore I Bax; Jurriaan E M de Steenwinkel
Journal:  J Infect Dis       Date:  2021-09-17       Impact factor: 7.759

Review 5.  MDR Tuberculosis Treatment.

Authors:  Juan Espinosa-Pereiro; Adrian Sánchez-Montalvá; Maria Luisa Aznar; Maria Espiau
Journal:  Medicina (Kaunas)       Date:  2022-01-26       Impact factor: 2.430

Review 6.  Application of Next Generation Sequencing for Diagnosis and Clinical Management of Drug-Resistant Tuberculosis: Updates on Recent Developments in the Field.

Authors:  Navisha Dookie; Azraa Khan; Nesri Padayatchi; Kogieleum Naidoo
Journal:  Front Microbiol       Date:  2022-03-24       Impact factor: 5.640

7.  Delamanid or pretomanid? A Solomonic judgement!

Authors:  Saskia E Mudde; Anna M Upton; Anne Lenaerts; Hannelore I Bax; Jurriaan E M De Steenwinkel
Journal:  J Antimicrob Chemother       Date:  2022-03-31       Impact factor: 5.790

Review 8.  Chemical Classes Presenting Novel Antituberculosis Agents Currently in Different Phases of Drug Development: A 2010-2020 Review.

Authors:  Klaudia T Angula; Lesetja J Legoabe; Richard M Beteck
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-13

9.  Comparison of in vitro Susceptibility of Mycobacteria Against PA-824 to Identify Key Residues of Ddn, the Deazoflavin-Dependent Nitroreductase from Mycobacterium tuberculosis.

Authors:  Fuzhen Zhang; Shanshan Li; Shuan Wen; Tingting Zhang; Yuanyuan Shang; Fengmin Huo; Yi Xue; Ling Li; Yu Pang
Journal:  Infect Drug Resist       Date:  2020-03-11       Impact factor: 4.003

Review 10.  Profiling Pretomanid as a Therapeutic Option for TB Infection: Evidence to Date.

Authors:  Stephani L Stancil; Fuad Mirzayev; Susan M Abdel-Rahman
Journal:  Drug Des Devel Ther       Date:  2021-06-28       Impact factor: 4.162
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.